AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
Phase 3positiveetentamigPositive
AI Analysis
Summary
AbbVie's etentamig achieved survival benefit in a Phase 3 multiple myeloma trial, with analysts noting its cleaner safety profile and convenient dosing schedule compared to other BCMA-targeting therapies.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
delivered survival benefit
Importance:8/10
Sentiment:
0.75
phase 3multiple myelomaT cell engagerBCMA-targetingsurvival benefit
Related Companies
Read the original article
Published by BioSpace on September 4, 2026 11:31 AM